Myomo to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceBusiness Wire • 09/07/22
Myomo Receives Order from the Louis Stokes Cleveland VA Medical Center to Support MyoPro Clinical TrialBusiness Wire • 08/30/22
Myomo, Inc.'s (MYO) CEO Paul Gudonis on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/06/22
Myomo Reports Second Quarter 2022 Financial Results and Record Number of Patient Pipeline AdditionsBusiness Wire • 08/03/22
Myomo Announces Second Quarter Preliminary Revenue and Record Pipeline AdditionsBusiness Wire • 07/07/22
Myomo, Inc. (MYO) CEO Paul Gudonis on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/11/22
Myomo Reports Progress with China Joint Venture, Receives Partial Payment of Technology License FeeBusiness Wire • 04/04/22
Myomo, Inc. (MYO) CEO Paul Gudonis on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/10/22
Myomo to Report Fourth Quarter and Full Year 2021 Financial Results on March 9, 2022Business Wire • 03/02/22
Myomo Strengthens Intellectual Property Portfolio With Receipt of Key Patent in JapanBusiness Wire • 02/17/22
Independent Research with Myomo's MyoPro® Shows Clinically Significant Gains in Motor Function in Individuals with Chronic Moderate-to-Severe Arm WeaknessBusiness Wire • 02/14/22
Myomo Amends China Joint Venture Agreement, Executes Technology and Trademark License AgreementBusiness Wire • 01/05/22
Myomo, Inc. (MYO) CEO Paul Gudonis on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21